Brolucizumab–dbll

(Beovu®)

Beovu®

Drug updated on 4/18/2024

Dosage FormInjection (intravitreal; 6 mg/0.05 mL)
Drug ClassVascular endothelial growth factor inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD).
  • Indicated for the treatment of diabetic macular edema (DME).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Brolucizumab (Beovu) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration and diabetic macular edema. It has demonstrated potential advantages in efficacy over other anti-vascular endothelial growth factor agents, showing significant improvement in best-corrected visual acuity and central subfield macular thickness.
  • The information was derived from 11 systematic reviews/meta-analyses that compared brolucizumab's safety and effectiveness with other drugs used to treat these conditions.
  • In patients with recalcitrant neovascular age-related macular degeneration, switching to brolucizumab after other treatments leads to significant morphological improvement despite potential side effects.
  • Compared to most other anti-VEGF treatments like ranibizumab and aflibercept, Beovu showcased superior reductions in retinal thickness. Its efficacy in improving BCVA was comparable to aflibercept but required fewer injections, which could indicate better patient adherence due to less treatment burden.
  • While promising results have been shown regarding its efficacy, concerns about Beovu's safety were raised, particularly around the incidence of retinal vasculitis and vascular occlusion. Most events happened within a short period after administration, indicating a notably high rate of serious ocular adverse events compared to Lucentis or Aflibercept.
  • The drug’s complex safety profile shows comparable rates of serious adverse events as well as higher frequencies of specific sight-threatening effects at certain doses when compared with similar medications such as Ranibizumab or Aflibercept.
  • Studies underscored the importance of population characteristics such as baseline severity conditions and prior treatment history on outcomes; it performed distinctively well among rnAMD patients previously treated by different anti-VEGFs.
  • Achieving a ≥12-week interval using this medication indicates a reduced treatment burden, significantly impacting long-term therapy management and quality-of-life considerations.

Product Monograph / Prescribing Information

Document TitleYearSource
Beovu (brolucizumab–dbll) Prescribing Information.2023Novartis Pharmaceuticals Corporation, East Hanover, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Safety and efficacy of brolucizumab in the treatment of diabetic macular edema and diabetic retinopathy: a systematic review and meta-analysis.2024Seminars in Ophthalmology
Efficacy and safety of brolucizumab, aflibercept, and ranibizumab for the treatment of patients with visual impairment due to diabetic macular oedema: a systematic review and network meta-analysis.2023Diabetes Therapy
Retinal vasculitis or vascular occlusion after brolucizumab for neovascular age-related macular degeneration: a systematic review of real-world evidence.2023Retina
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.2023Cochrane Database Systematic Reviews
Brolucizumab in pretreated neovascular age-related macular degeneration: case series, systematic review, and meta-analysis.2023Life
The efficacy and safety of brolucizumab for the treatment of nAMD: a systematic review and meta-analysis.2022Frontiers in Pharmacology
Comparative efficacy of brolucizumab in the treatment of neovascular age-related macular degeneration: a systematic literature review and network meta-analysis.2022Advances in Therapy
Managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression.2022Journal of Clinical Medicine
Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis.2021Systematic Reviews
Effect of anti‐VEGF therapy on the disease progression of neovascular age‐related macular degeneration: a systematic review and model‐based meta‐analysis.2021Journal of Clinical Pharmacology
Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis.2021Graefe's Archive for Clinical and Experimental Ophthalmology